what is aod-9604 peptide: Frequently asked questions

Verify peptide reconstitution and storage first. Lyophilised AOD 9604 must be reconstituted in sterile water or bacteriostatic saline and stored at 2-8°C; any temperature excursion above 8°C degrades the peptide irreversibly. The beta-3 adrenergic receptor expression varies significantly across species and adipose depots. Rodent models show stronger responses than primate models, and visceral fat responds more robustly than subcutaneous fat. If using an in vitro adipocyte model, confirm beta-3 receptor expression through qPCR; some immortalised cell lines lack functional beta-3 receptors entirely. Finally, consider the assay endpoint. AOD 9604 increases free fatty acid release, not necessarily net fat oxidation; without a metabolic sink (exercise, fasting conditions, or pharmacological energy expenditure increase), liberated fatty acids may re-esterify without observable fat loss.

Reject it. AOD 9604 is unstable in aqueous solution at room temperature. Degradation begins within 48-72 hours even under refrigeration. Lyophilised powder stored at -20°C remains stable for 12-24 months; pre-mixed solutions do not. If a supplier ships AOD 9604 pre-reconstituted, it suggests either poor handling protocols or a product that was never lyophilised to begin with. At Real Peptides, every AOD 9604 batch is supplied as lyophilised powder with verified sequence integrity. Pre-mixed peptides are a red flag for compromised stability and unreliable experimental outcomes.

Run parallel arms with matched dosing schedules, but expect divergent timelines. HGH effects build over days to weeks as IGF-1 synthesis accumulates, while AOD 9604 acts within hours. Measure distinct endpoints: for hGH, track IGF-1, fasting glucose, and nitrogen balance alongside lipolysis markers; for AOD 9604, focus on free fatty acid kinetics, glycerol release, and beta-3 receptor expression without expecting anabolic or glycaemic changes. This design isolates which effects derive from lipolysis alone versus GH receptor-mediated pathways. If comparing body composition outcomes, note that hGH produces lean mass gain that may offset fat loss on a scale, while AOD 9604 has no such anabolic component.

If reconstituted AOD-9604 peptide has been stored above 8°C for more than 4 hours, its stability is compromised. Peptide bonds begin hydrolyzing at ambient temperature, and the degradation is irreversible. You won't see visible changes, but lipolytic activity decreases proportionally to thermal exposure duration. For protocols requiring precise dose-response data, discard any peptide exposed to temperature excursions. Unreconstituted lyophilized powder tolerates brief ambient exposure (up to 24 hours at 25°C), but long-term storage must occur at −20°C.

Discard it immediately and do not use it for research. Cloudiness, discoloration, or visible particulates indicate protein aggregation or contamination. Both of which render the peptide inactive and introduce confounding variables into any assay. Properly reconstituted AOD-9604 peptide should be clear and colorless. Aggregation occurs when the peptide is reconstituted with the wrong diluent (sterile water instead of bacteriostatic water), exposed to temperatures above 8°C, or shaken vigorously during mixing. Always add diluent slowly down the vial wall and swirl gently. Never shake.

First, verify reconstitution concentration and confirm that the dosing calculation matches the intended microgram-per-kilogram target. The most common error is miscalculating peptide concentration after reconstitution. Using 1 mL instead of 2 mL bacteriostatic water doubles the concentration and can push dosing into a range where receptor saturation plateaus without additional effect. Second, confirm that the peptide source provided certificate of analysis (CoA) data showing >98% purity via HPLC. Lower purity indicates degraded or incorrectly synthesized product. If both factors are confirmed, consider that AOD-9604 peptide's mechanism requires functional beta-3 adrenergic receptors on adipose tissue; genetic knockout models or beta-blocker pre-treatment will abolish the response entirely.